

## HAPPY NOW?

## Four questions on the European banks' stress test

**Question 1: Will the sector bounce strongly?** The US bank sector surged 70% around the time of its stress test, but we do not think Europe will follow suit. The US stress test proved the catalyst for massive equity recapitalisations, coincided with an economic recovery, and was performed on a sector trading one-third below its long-run valuation. We believe the July 2010 European stress test is unlikely to lead to any meaningful capital raising, was released at a time of growing economic uncertainty, and has been conducted on a sector trading within 10% of its long-run valuation.

**Question 2: Is the test credible?** We give a qualified "yes". Two year loan losses of 3.6% represent 30-year highs for the sector but are dwarfed by the US's 9% stressed level. Whilst such comparisons can be misleading, there does appear to be more individual bank "wiggle room" for European banks, which we see as disappointing. In addition, pre-provision profit assumptions feel optimistic. There are substantial differences by country; in Spain, for example, the assumption is for a cumulative decline in commercial property prices of 55%, yet for just 7% in Greece. This may reflect an element of delayed recognition in Spain. The absence of testing for full sovereign default is understandable, but new disclosure allows investors to conduct their own stress test.

**Question 3: Who was the stress test done for?** Our view is not for us in equities, but for the debt markets. Whilst the US test last year was conducted in the shadow of nationalisation risk, this test was prompted by a renewed funding crisis. Indeed shareholders' equity has not even been tested. So what is the debt market likely to make of it? We see a "cautious welcome" as the likely view.

**Question 4: Will funding costs come down?** This is perhaps the key question. To the extent that the market feared what it did not know, the full sovereign risk disclosure is likely to be a positive. However, much of the sector's funding pressure is, in our view, structural: too many balance sheets (banks and sovereigns) chasing too few funds. With or without a stress test, Europe's banks still have €1.5trn of debt maturing by 2012, as well as the need to repay over €500bn to central banks. Well-capitalised banks with limited exposure to SGIIIP (Spain, Greece, Ireland, Italy, Portugal) sovereigns, such as HSBC and BNP Paribas, should continue to be best placed to benefit. Of the big caps in Europe, BBVA appears to us the weakest positioned. We suspect structurally higher overall funding costs – and the differential in costs among banks – are set to remain.

Barclays Capital does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report.

Investors should consider this report as only a single factor in making their investment decision.

This research report has been prepared in whole or in part by research analysts based outside the US who are not registered/qualified as research analysts with FINRA.

PLEASE SEE ANALYST(S) CERTIFICATION(S) AND IMPORTANT DISCLOSURES BEGINNING ON PAGE 15.

## INDUSTRY UPDATE

## European Banks

2-NEUTRAL

Unchanged

Simon Samuels  
+44 (0)20 3134 3364  
simon.samuels@barcap.com  
Barclays Capital, London

Mike Harrison  
+44 (0)20 3134 3056  
mike.harrison@barcap.com  
Barclays Capital, London

## European Banks

Simon Samuels

Jeremy Sigee

Tom Rayner

Kiri Vijayarajah

Rohith Chandra-Rajan

Mike Harrison


Antonio Rizzo

Carlos Cobo Catena

## Question 1: Will the sector bounce strongly?

Our view is probably not. At the headline level the results are “better” than expected, with a 92% pass rate (ie, 7 failures) against expectations of a 75%-85% pass rate (ie, 15-20 failures). As Figure 1 shows, our entire quoted universe passed, with MPS closest to the 6% failure level.

Figure 1: Stress test –results




Source: CEBS

But as any parent bemoaning the grade inflation that appears to have made their children's exams easier knows, the result of any test is entirely a function of the difficulty level set. We discuss below (*Question 2*) just how credible we view this test to be.

However, one view might be that perhaps it does not matter that we can poke around and find faults. It is easy to criticize, but the high-level message of the stress test should not be completely ignored: European banks only need €3.5bn to cope with a return of recession conditions and a degree of “sovereign shock”. Given this benign outcome, could not the European bank sector rally sharply, as indeed the US sector did around the time of its stress test (Figure 2)?

Figure 2: Performance of US banks before, during and after US stress test




Source: Datastream, Federal Reserve Bank of New York, Barclays Capital

Despite only a 47% pass rate, the US stress test in May 2009 was initially viewed by many commentators as also not very credible. Yet the test proved crucial to the rehabilitation of the sector, representing a key catalyst for significant equity capital raising (\$130bn over the remainder of 2009). Arguably that is the first, most obvious difference with the US then and Europe now: the US sector actually did raise capital on the back of the stress test. Europe, in our view, does not need to.


But perhaps the more important difference with the May 2009 test is that it coincided with signs of economic recovery; as Figure 3 shows, US consumer and manufacturing sentiment had already turned decisively by spring 2009. By contrast, the economic outlook in July 2010 is clouded by renewed concerns of slowing economic growth. As a sentiment gauge, the Baltic Dry Index of worldwide shipping prices shows this divergence clearly; in the month leading up to the US stress test it jumped by one-third (and carried on rising), whereas over the month leading to the European stress test results the same index has fallen by one-third (Figure 4).

Figure 3: US economic indications, 2008-present



Source: Datastream

Figure 4: Baltic Dry Index – Before and after stress tests



Source: Bloomberg, Barclays Capital

Perhaps as important for bank share prices at the time was the statement by the US government on 23 February 2009 that the presumption underpinning the stress tests would be for banks to "remain in private hands": a statement which, given the continued concerns over the fate of (especially) Citigroup, sparked a sector recovery. Indeed, as shown in Figure 2, that February 23rd date is far closer to the sector's trough than the 7 May stress test results day.

However, perhaps the bigger constraint on a European sector rally from here is valuation. Currently the European banking sector is trading on 1.25x tangible book. That represents only a modest discount to the 30-year average (1.4x). By contrast, back in May 2009 the US banks were trading on almost a 30% discount to their 30-year average.

Figure 5: Valuation comparison, US vs. European banks around stress test

	Price to tangible book		Divergence from 30-year averages		Standard deviations	
	US banks	European banks	US banks	European banks	US banks	European banks
3 months prior to stress test	1.02x	1.37x	-46%	-2%	-1.04	-0.04
2 months prior to stress test	1.24x	1.15x	-35%	-18%	-0.79	-0.37
1 month prior to stress test	1.35x	1.22x	-29%	-13%	-0.67	-0.26
At stress test date	1.34x	1.25x	-29%	-11%	-0.68	-0.22
30-year average PTBV	1.94x	1.40x				


Source: Barclays Capital

## Question 2: Is the test credible?

Given the almost 100% pass rate, the next key question is whether this test is viewed as credible. Given that the European stress test was conducted *after* a deep recession, the severity of the stressed downturn was always going to be much more modest than that used in the US stress test.

So what do we think of the assumptions used? The main economic assumption – a 3% GDP divergence from current forecast over a two-year period – had already been disclosed and compared to a 2.9% deviation in the US stress test. At the individual country level, that GDP divergence would mean renewed recession for 18 (out of 27) countries for 2010 and for 13 in 2011. The impact on unemployment from moving from benchmark to adverse scenario is shown below (Figure 6). For comparison, in the US stress test the increase in unemployment in the adverse scenario was 1.4%. In this context, the GDP assumptions for the EU stress test appear broadly sensible; the unemployment shock perhaps a little benign.


Figure 6: Change in unemployment rate in adverse scenario



Source: CEBS, Federal Reserve


However, perhaps the more interesting assumptions to analyse are property prices. Figures 7 and 8 show the two-year (2010 and 2011) cumulative decline in commercial and residential property prices. The massive decline in Spain is striking, both in absolute terms and also relative to other major countries in Europe. Clearly asset prices have risen more in Spain, which will explain much of the difference, but there will also be inevitably a suspicion that there is a component of delayed loss recognition in the cumulative asset price decline projections. The US stress test did not include an explicit commercial property assumption but it did include a 27% two-year decline in residential property prices.

Figure 7: Cumulative decline in commercial property prices 2010-2011 incorporated in stress test



Source: CEBS


Figure 8: Cumulative decline in residential property prices 2010-2011 incorporated in stress test



Source: CEBS, Federal Reserve

The GDP variation, increase in unemployment, and forecast decline in property prices together result in a Europe-wide loan book loss rate of 1.6% before the impact of a “sovereign shock”, rising to 2% with sovereign shock included. To be clear, this increase post-sovereign shock is unrelated to any banking book losses on sovereign exposures themselves, but rather is the forecast impact of higher borrowing costs arising from higher sovereign spreads. At the 2% level, impairments would be around 20% higher than the 2009 level, itself a 30-year high.

Figure 9: European credit impairment charge – Historic, forecast & stress test




Source: Worldscope, Company Reports, CEBS, Barclays Capital

Whilst the impairment losses in the adverse scenario would represent 30-year peaks, the level is much lower than that applied in the US stress test (9.1%). We believe the two numbers are essentially incomparable, given that 1) the July 2010 stress test comes *after* a deep recession; and 2) the loan books of the two banking sectors are very different, due largely to the distorting impact of Freddie Mac and Fannie Mae. Specifically, for the 19

banks included in the US stress test, only 9% of their portfolio was first lien mortgagees, compared to nearer one third for the European bank sector.


Figures 10 and 11 compare two-year impairment losses split between corporate loans and retail loans. Banks in the most stressed economies (Spain, Greece, Ireland) and with the highest proportion of higher risk unsecured credit (HSBC in the US, UK banks) incorporate the highest forecast loss rates.

Figure 10: 2yr corporate loan losses (adverse & sovereign shock)



Source: CEBS, Federal Reserve,

Figure 11: 2yr retail loan losses (adverse & sovereign shock)



Source: CEBS

Nevertheless, we feel it is still fair to say that this European stress test appears to have more “wiggle room”. The estimates used in the US stress test also incorporated loan-specific details on past performance, origination year, borrower characteristics and geographic distribution, as well as disclosure of estimated losses across eight separate loan book elements (vs two in Europe). Additionally, the Committee of European Banking Supervisors (CEBS) has adopted only a “top down approach for smaller and less complex banks”. This, we believe, reduces the credibility of the European stress test compared to the US equivalent.

### Sovereign shock is not sovereign default

Moreover, the “sovereign shock” modeled by the CEBS focuses only on government bond exposures in trading books and the associated impairment losses on commercial loans (with higher government yields leading to more defaults in the real economy). AFS and hold-to-maturity portfolios are not explicitly tested for sovereign losses. Whilst this is perhaps understandable from both an accounting point of view and in view of the presence of EU/IMF bailout funds, it should be noted that the US stress test took a more conservative approach, focusing “on whether...it is more-likely-than-not that firms will be required to sell the security before recovery of its cost base”. Furthermore, given that the catalyst for a European stress test was fears over bank sovereign exposures, concentrating only on trading book assets may provide limited reassurance.

### Pre-provision profits – How conservative?

Impairment losses in the adverse scenario are forecast to total €473bn (or €522bn with sovereign shock). This is almost fully offset by forecast pre-provision profits of €507bn. To give some context, pre-provision profits for the 91 banks included in the stress test totaled €270bn in 2009, implying that the adverse scenario with sovereign shock would experience pre-provision profits running just 6% below 2009 levels.

Instinctively this feels generous. The experience of 2007-2009 was that pre-provision earnings fell sharply across the sector (by around one-third), clearly impacted by structured credit write-downs and other capital market losses which we would not expect to be repeated. Nevertheless, just a 6% fall still looks optimistic. Indeed, we suspect the CEBS was itself somewhat suspicious of this outcome, describing it as a “somewhat positive outlook”. Specifically, the CEBS suggests that the “zero growth” assumption built into the exercise may actually prove too optimistic for those banks that are deliberately shrinking.

Figure 12 shows how the pre-provision profit forecasts included in the adverse scenario compare to our own forecasts for pre-provision profits. Comparisons are difficult – not least because the stress test assumes a static balance sheet. Moreover, our forecasts are of course effectively based on the benchmark scenario whilst the stress test numbers are based on the adverse scenario. Hence we would expect our forecasts to be higher than the benchmark scenario, and in most cases they are. (Unfortunately the stress test does not disclose estimated pre-provision profits in the benchmark scenario). Indeed, for only two banks – Deutsche Bank and Credit Agricole – is the CEBS number higher than our forecast. For Credit Agricole this reflects the different scope of the business being stressed (our forecast is for Credit Agricole S.A whereas the stress test applied to the entire group). For Deutsche Bank, we understand this difference largely reflects financial asset impairments being added back to pre-impairment income and then subsequently deducted. At the other extreme, we understand that the very weak estimate of pre-provision profits for both Deutsche Postbank and KBC reflects the impact of a simultaneous rise in short-term and long-term interest rates which – due to the additional assumption that their investment portfolio is unchanged (the “zero growth assumption”) – damages their margins.



Figure 12: Analysis of pre-provision profits included in stress test

	2005	2006	2007	2008	2009	2010E	2011E	Cumulative 2010/11	BarCap forecast cumulative 2010/11	Per stress test cumulative 2010/11	Stress test PPP vs Barcap
	€m	€m	€m	€m	€m	€m	€m	€m	Local Currency	Local Currency	
AIB	1,643	2,006	2,335	2,605	1,989	1,569	1,606	3,175	3,175	901	-72%
Deutsche Postbank	945	1,305	1,307	-658	224	1,177	1,323	2,500	2,500	1,023	-59%
KBC	3,471	4,775	4,640	-771	-5	4,432	3,212	7,644	7,644	3,279	-57%
UBI	1,692	1,755	2,051	1,637	1,556	1,296	1,855	3,151	3,151	2,411	-23%
Unicredit	7,988	11,976	13,346	10,190	12,248	11,606	13,346	24,951	24,951	20,374	-18%
MPS	1,747	1,865	1,787	2,020	2,043	2,290	2,830	5,120	5,120	4,350	-15%
Commerzbank	1,765	2,910	2,830	2,329	1,713	4,028	4,214	8,242	8,242	7,009	-15%
SocGen	7,010	8,714	7,618	6,338	5,964	9,441	9,646	19,087	19,087	16,774	-12%
Santander	8,910	11,218	14,840	18,540	22,960	24,848	26,473	51,320	51,320	45,737	-11%
HSBC	22,630	25,383	27,114	23,932	26,939	25,962	26,896	52,858	68,646	61,442	-10%
SEB	1,346	1,752	1,864	1,630	1,489	1,353	1,627	2,980	2,980	2,668	-10%
BBVA	6,813	8,340	9,641	10,523	12,308	11,721	12,045	23,766	23,766	21,768	-8%
Swedbank	1,649	1,519	1,752	1,911	1,593	1,339	1,508	2,847	2,847	2,720	-4%
BNP Paribas	8,485	10,878	12,273	8,976	16,851	16,080	16,498	32,578	32,578	32,001	-2%
LBG (pro forma with HBOS)	15,997	18,590	18,860	11,439	12,215	14,078	14,854	28,932	24,519	24,444	0%
RBS	14,562	16,563	14,663	-1,197	8,816	12,222	15,223	27,445	23,258	24,219	4%
Intesa Sanpaolo	4,383	8,287	9,250	7,990	8,161	7,856	8,879	16,735	16,735	17,782	6%
Bk of Ireland	1,419	1,759	2,004	1,871	1,409	1,131	1,094	2,225	2,225	2,482	12%
Deutsche Bank	6,197	8,337	8,876	-4,998	8,644	7,885	8,142	16,027	16,027	21,775	36%
Credit Agricole	4,527	5,832	4,050	3,321	5,760	6,802	7,538	14,340	14,340	22,611	58%

Source: CEBS and Barclays Capital


### Question 3: Who was the stress test done for?

The US stress test was clearly done for the equity market, in our view. In the period leading up to it there were growing concerns that the US banking industry was on the verge of being nationalised, especially in light of the rescues of both Citigroup and Bank of America in the period leading up to the test. The government preference shares that were injected via the TARP process boosted reported Tier 1 ratios yet did nothing for equity Tier 1 ratios. It was clear that shareholders' equity was vulnerable and hence the test was focused on stressing both Tier 1 and Tier 1 common. And it was the Tier 1 common test that proved the harsher of the two to satisfy.<sup>1</sup>

The European stress test is very different. We do not see it as primarily being done as an exercise for the equity market. The pressure for a European-wide stress test emerged in direct response to the severe pressures in the funding market that developed during April and May 2010. Indeed, equity capital itself is not even being tested, but instead Tier 1 capital. That reflects several things, not least the fact that the European bank sector today has much higher equity Tier 1 (or Tier 1 common) ratios than the US banks had in May 2009. Figure 13 illustrates this.

<sup>1</sup> Indeed, the vast majority of the €185bn capital shortfall in the US stress test came from a shortfall in Tier 1 common – with virtually no shortfall in overall Tier 1 capital.

Figure 13: Equity Tier 1 ratios at time of stress test – Europe &amp; US




Source: Barclays Capital

Of course we can do our own US-style equity Tier 1 stress. Figure 14 takes the results of the adverse scenario plus sovereign shock and shows our estimate of what that would do to equity Tier 1 ratios. It suggests that four banks of our covered universe that were subject to a stress test – RBS, KBC, Commerzbank and Deutsche Postbank – would fail the 4% equity Tier 1 ratio threshold that was applied in the US stress test. But as noted, we do not see this as especially important since the test is not for equity holders but debt counterparties.

Indeed, as we discuss below, perhaps the single most important thing to emerge from the stress test is not the result itself but the new disclosure on sovereign risk, which we expect will help remove some of the uncertainty in funding markets for some of the more stressed names.

Figure 14: 2011 Equity Tier 1 ratios post-adverse scenario &amp; sovereign shock



Source: CEBS, Barclays Capital

## Question 4: Will funding costs come down?

Given our view that the real audience of this stress test is the debt market, the final but most important question is, what will the debt market think of the stress test? Will it lower funding costs? Will it “work”?

We have discussed this in some detail with our colleagues in both the rates and credit space and we believe the comments below are consistent with their views.


Funding costs for all banks are elevated at the moment – but importantly, vary substantially among banks. Higher bank funding costs can be explained by a combination of cyclical and structural factors. Cyclical because bond spreads typically rise in periods of economic distress or uncertainty; and structural because there are too many balance sheets (banks, sovereigns, private equity etc) chasing too few funds.

Whilst just €3.5bn of recapitalisation is being required under the stress test, far less than most commentators had predicted, we still think that overall the stress test helps funding conditions for banks insofar as uncertainty is reduced. As an example, there have been widespread concerns about Spanish banks (of all sizes) encountering funding problems in the past 2-3 months. Given that all the listed Spanish banks are shown to be comfortably solvent even after (amongst other things) testing for a 55% decline in commercial real estate prices, we anticipate that their access to funding markets is likely to improve following the stress test.

Is the funding situation helped by the additional sovereign disclosure? Again, probably yes. The publication of exposures shifts risk from the systemic to the idiosyncratic; banks passing the stress test by particularly wide margins could benefit most. Indeed, one result of having a stress test which “everyone” passes is that the market itself reinforces the funding winners/losers distinction.

To look at this, we use the additional sovereign disclosure to extend the stress test and take two approaches. First, in Figure 15 we apply the same haircuts on sovereign exposures in the trading book to the banking book to gauge the impact on Tier 1<sup>2</sup>.

**Figure 15: Tier 1 Ratios before and after banking book sovereign stress**




Source: CEBS, Barclays Capital

<sup>2</sup> We take Tier 1 because, in general, funding markets only care about how big a buffer they have, not the composition of that buffer. We make the simplifying assumption that Tier 1 counts more as “capital” than as “funding”.

Second, as a more draconian test of peripheral European exposures, in Figure 16 we double the banking book haircuts for Greece (to 46%), Spain (to 24%), Portugal (to 28%), Ireland (to 26%) and Italy (to 15%), but leave the other sovereign exposures untouched. Under both scenarios, most banks see their Tier 1 ratios remain above 6% and virtually all are above the 4% regulatory minimum. In aggregate then, the incremental disclosure should help ease funding pressures. In terms of individual stocks, it is perhaps worth pointing out that SocGen appears better placed than either BNP Paribas or Credit Agricole<sup>3</sup>; Santander better than BBVA; the larger cap Italians (Unicredit and Intesa SanPaolo) better than their mid-cap counterparts; and Bank of Ireland better than Allied Irish. Probably unsurprisingly, all of the UK and Nordic banks have relatively small exposures.

**Figure 16: Tier 1 Ratios before and after doubling the SGIIIP haircuts**



Source: CEBS, Barclays Capital

However, it should be noted that passing an extended stress test based on sovereign exposures only provides a partial answer. A scenario whereby Spanish sovereign debt trades with a 28% haircut would almost certainly also mean an even more severe credit quality environment than stress-tested for by the CEBS.

As an aside, one thing that surprised us was how small Lloyds Banking Group's exposure to European sovereign risk is, both to SGIIIP countries and others. Overall Lloyds reports just £8bn of European exposure in the stress test, whereas at the end of 2009 it reported "primary liquidity"<sup>4</sup> of £88bn – far more in line with banks of similar size – with another £62bn of "secondary liquidity". This repositioning of the balance sheet is clearly a benefit in terms of getting through the stress test, but might this potentially signify a less liquid balance sheet?

Of course, any stress test that we perform here is, essentially, arbitrary. As such, in Figure 17, we include a more conservative measure of SGIIIP exposure, the total "unstressed" SGIIIP sovereign exposure as a proportion of Tier 1. If the situation for SGIIIP economies deteriorates (further), then the realised pain that each bank experiences may be rather different to that shown in the stress test in Figure 16. Hence, this approach helps to tease

<sup>3</sup> However, of the 3 French banks, BNP Paribas is the only one that doesn't have a commercial banking business in Greece, which is excluded from our analysis in Figure 16

<sup>4</sup> UK Gilts, US Treasuries, Euro AAA government debt; unencumbered cash balances held at Central banks

out additional differences we see among banks – which essentially magnifies the differences identified in Figure 16.

**Figure 17: Analysis of SGIIP exposures**

	-----SGIIP exposures-----		% other sovereigns	Not tested
	% tested (trading book)	% not tested (banking book)	Not tested (banking book)	SGIIP as % Tier 1
NBG	8%	92%	92%	344%
MPS	32%	68%	59%	252%
BBVA	17%	83%	62%	171%
Dexia	5%	95%	93%	150%
Intesa SanPaolo	35%	65%	68%	137%
Banco Popular	0%	100%	None	130%
Alpha Bank	3%	97%	99%	121%
Sabadell	0%	100%	Negligible	119%
Allied Irish Bank	0%	100%	100%	115%
UBI	14%	86%	92%	93%
Bankinter	4%	96%	Negligible	83%
Santander	23%	77%	23%	76%
KBC	13%	87%	91%	73%
Unicredit	40%	60%	84%	66%
Commerzbank	1%	99%	89%	63%
BNP Paribas	6%	94%	96%	49%
Danske Bank	56%	44%	36%	30%
Erste	1%	99%	84%	22%
Bank of Ireland	0%	100%	0%	20%
Societe Generale	40%	60%	86%	19%
Credit Agricole	58%	42%	83%	14%
RBS	46%	54%	77%	12%
Barclays	16%	84%	82%	10%
SEB	0%	100%	79%	6%
Nordea	32%	68%	84%	3%
HSBC	87%	13%	59%	1%
Lloyds Banking Group	0%	100%	96%	0%
Swedbank	None	None	34%	0%
SHB	None	None	35%	0%
DnB NOR	100%	0%	0%	0%

Source: CEBS


Of course, the materiality of this analysis is dependent on how sensitive each bank is to a change in the market perception of its SGIIP-related risk. After all, if the market is not worried about a particular bank's sovereign exposure, then additional disclosure that confirms this view will have limited price impact.

To this end, Figure 18 measures the average year-to-date price change of each European bank when the CDS spread of one of the SGIIP sovereigns increases by more than 20bps. In

other words, which banks have sold off most when SGIIP sovereign risk has increased? Some of the results are hardly surprising: for instance, NBG and Alpha Bank show strong sensitivity, whilst HSBC, Standard Chartered and several Nordic banks are more or less indifferent to "bad days" for SGIIPs. However, this analysis does yield some interesting comparisons when set against the findings from the additional stress test information.

For instance, Santander and BBVA behave pretty similarly on "bad days" – yet the previous analysis suggests that Santander is less at risk. Similarly, SocGen and Credit Agricole are far more sensitive than is BNP Paribas. Whilst this is understandable given SocGen and Credit Agricole's greater commercial exposure to Greece, the magnitude of the difference is perhaps too big, since the sovereign exposures for both appear manageable. Finally, both Unicredit and Intesa appear to have very similar resilience to a sovereign stress of the banking book – and yet this year, Unicredit has exhibited greater sensitivity to SGIIP distress.

Figure 18: YTD average daily price change when SGIIP CDS spread increases by 20bps or more



Source: DataStream, Barclays Capital

So we can perhaps glimpse a basis for differentiating among banks on funding, as a result of the stress test. But the stress test does little to improve the structural funding challenges facing European banks. We estimate that the industry has maturing term debt totaling €1.5trn by the end of 2012, which – when adding in the c €500bn of central bank liquidity that will need, at some stage, to be refinanced independently – suggests funding challenges remain.

## ANALYST(S) CERTIFICATION(S)

We, Simon Samuels, Mike Harrison, Jeremy Sigee, Tom Rayner, Kiri Vijayarajah, Rohith Chandra-Rajan and Antonio Rizzo, hereby certify (1) that the views expressed in this research report accurately reflect our personal views about any or all of the subject securities or issuers referred to in this research report and (2) no part of our compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

## IMPORTANT DISCLOSURES

For current important disclosures, including, where relevant, price target charts, regarding companies that are the subject of this research report, please send a written request to: Barclays Capital Research Compliance, 745 Seventh Avenue, 17th Floor, New York, NY 10019 or refer to <http://publicresearch.barcap.com> or call 1-212-526-1072.

The analysts responsible for preparing this research report have received compensation based upon various factors including the firm's total revenues, a portion of which is generated by investment banking activities.

Research analysts employed outside the US by affiliates of Barclays Capital Inc. are not registered/qualified as research analysts with FINRA. These analysts may not be associated persons of the member firm and therefore may not be subject to NASD Rule 2711 and incorporated NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst's account.

On September 20, 2008, Barclays Capital acquired Lehman Brothers' North American investment banking, capital markets, and private investment management businesses. All ratings and price targets prior to this date relate to coverage under Lehman Brothers Inc.

Barclays Capital produces a variety of research products including, but not limited to, fundamental analysis, equity-linked analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of research product may differ from recommendations contained in other types of research products, whether as a result of differing time horizons, methodologies, or otherwise.

### Materially Mentioned Stocks (Ticker, Date, Price)

Allied Irish Banks PLC (ALBK.I, 23-Jul-2010, EUR 0.90), 3-Underweight/2-Neutral  
Banca Monte dei Paschi di Siena (BMPS.MI, 23-Jul-2010, EUR 0.96), 1-Overweight/2-Neutral  
Banco Bilbao Vizcaya Argentaria S.A. (BBVA.MC, 23-Jul-2010, EUR 9.84), 3-Underweight/2-Neutral  
Banco Santander SA (SAN.MC, 23-Jul-2010, EUR 10.12), 3-Underweight/2-Neutral  
Bank of Ireland (BKIR.I, 23-Jul-2010, EUR 0.74), 3-Underweight/2-Neutral  
BNP Paribas (BNPP.PA, 23-Jul-2010, EUR 49.82), 1-Overweight/2-Neutral  
Commerzbank AG (CBKG.DE, 23-Jul-2010, EUR 6.44), 3-Underweight/2-Neutral  
Credit Agricole SA (CAGR.PA, 23-Jul-2010, EUR 9.36), 3-Underweight/2-Neutral  
Credit Suisse Group AG (CSGN.VX, 23-Jul-2010, CHF 44.33), 2-Equal Weight/2-Neutral  
Deutsche Bank AG (DBKGn.DE, 23-Jul-2010, EUR 49.75), 1-Overweight/2-Neutral  
Deutsche Postbank AG (DPBGn.DE, 23-Jul-2010, EUR 23.30), 2-Equal Weight/2-Neutral  
HSBC Holdings PLC (HSBA.L, 23-Jul-2010, GBP 6.46), 1-Overweight/2-Neutral  
Intesa Sanpaolo (ISP.MI, 23-Jul-2010, EUR 2.40), 2-Equal Weight/2-Neutral  
Julius Baer (BAER.VX, 23-Jul-2010, CHF 36.08), 2-Equal Weight/2-Neutral  
KBC Groep NV (KBC.BR, 23-Jul-2010, EUR 33.59), 1-Overweight/2-Neutral  
Lloyds Banking Group PLC (LLOY.L, 23-Jul-2010, GBP 0.64), 3-Underweight/2-Neutral  
Royal Bank of Scotland Group PLC (RBS.L, 23-Jul-2010, GBP 0.45), 1-Overweight/2-Neutral  
Skandinaviska Enskilda Banken AB (SEBa.ST, 23-Jul-2010, SEK 47.89), 2-Equal Weight/2-Neutral  
Société Générale (SOGN.PA, 23-Jul-2010, EUR 38.00), 2-Equal Weight/2-Neutral  
Standard Chartered PLC (STAN.L, 23-Jul-2010, GBP 18.24), 2-Equal Weight/2-Neutral  
Swedbank AB (SWEDa.ST, 23-Jul-2010, SEK 79.00), 1-Overweight/2-Neutral  
UBI Banca (UBI.MI, 23-Jul-2010, EUR 8.00), 2-Equal Weight/2-Neutral  
UBS AG (UBSN.VX, 23-Jul-2010, CHF 15.47), 3-Underweight/2-Neutral  
UniCredit (CRDI.MI, 23-Jul-2010, EUR 2.04), 1-Overweight/2-Neutral

### Other Material Conflicts

BBVA.MC: Barclays Bank PLC is associated with specialist firm Barclays Capital Market Makers, which makes a market in Banco Bilbao Vizcaya Argentaria stock. At any given time, the associated specialist may have "long" or "short" inventory position in the stock; and the associated specialist may be on the opposite side of orders executed on the Floor of the Exchange in the stock.

**IMPORTANT DISCLOSURES CONTINUED**

**BKIR.I:** Barclays Bank PLC is associated with specialist firm Barclays Capital Market Makers, which makes a market in Bank of Ireland stock. At any given time, the associated specialist may have "long" or "short" inventory position in the stock; and the associated specialist may be on the opposite side of orders executed on the Floor of the Exchange in the stock.

**HSBA.L:** Barclays Bank PLC is associated with specialist firm Barclays Capital Market Makers, which makes a market in HSBC Holdings PLC stock. At any given time, the associated specialist may have "long" or "short" inventory position in the stock; and the associated specialist may be on the opposite side of orders executed on the Floor of the Exchange in the stock.

**LLOY.L:** Barclays Bank PLC is associated with specialist firm Barclays Capital Market Makers, which makes a market in Lloyds Banking Group PLC stock. At any given time, the associated specialist may have "long" or "short" inventory position in the stock; and the associated specialist may be on the opposite side of orders executed on the Floor of the Exchange in the stock.

**SAN.MC:** Barclays Bank PLC is associated with specialist firm Barclays Capital Market Makers, which makes a market in Banco Santander SA stock. At any given time, the associated specialist may have "long" or "short" inventory position in the stock; and the associated specialist may be on the opposite side of orders executed on the Floor of the Exchange in the stock.

**Guide to the Barclays Capital Fundamental Equity Research Rating System:**

Our coverage analysts use a relative rating system in which they rate stocks as 1-Overweight, 2-Equal Weight or 3-Underweight (see definitions below) relative to other companies covered by the analyst or a team of analysts that are deemed to be in the same industry sector (the "sector coverage universe").

In addition to the stock rating, we provide sector views which rate the outlook for the sector coverage universe as 1-Positive, 2-Neutral or 3-Negative (see definitions below). A rating system using terms such as buy, hold and sell is not the equivalent of our rating system. Investors should carefully read the entire research report including the definitions of all ratings and not infer its contents from ratings alone.

**Stock Rating**

**1-Overweight** - The stock is expected to outperform the unweighted expected total return of the sector coverage universe over a 12-month investment horizon.

**2-Equal Weight** - The stock is expected to perform in line with the unweighted expected total return of the sector coverage universe over a 12-month investment horizon.

**3-Underweight** - The stock is expected to underperform the unweighted expected total return of the sector coverage universe over a 12-month investment horizon.

**RS-Rating Suspended** - The rating and target price have been suspended temporarily due to market events that made coverage impracticable or to comply with applicable regulations and/or firm policies in certain circumstances including when Barclays Capital is acting in an advisory capacity in a merger or strategic transaction involving the company.

**Sector View**

**1-Positive** - sector coverage universe fundamentals/valuations are improving.

**2-Neutral** - sector coverage universe fundamentals/valuations are steady, neither improving nor deteriorating.

**3-Negative** - sector coverage universe fundamentals/valuations are deteriorating.

Below is the list of companies that constitute the "sector coverage universe":

**European Banks**

Allied Irish Banks PLC (ALBK.I)	Banca Monte dei Paschi di Siena (BMPS.MI)	Banco Bilbao Vizcaya Argentaria S.A. (BBVA.MC)
Banco Santander SA (SAN.MC)	Bank of Ireland (BKIR.I)	BNP Paribas (BNPP.PA)
Commerzbank AG (CBKG.DE)	Credit Agricole SA (CAGR.PA)	Credit Suisse Group AG (CSGN.VX)
Deutsche Bank AG (DBKGn.DE)	Deutsche Postbank AG (DPBKn.DE)	HSBC Holdings PLC (HSBA.L)
Intesa Sanpaolo (ISP.MI)	Julius Baer (BAER.VX)	KBC Groep NV (KBC.BR)
Lloyds Banking Group PLC (LLOY.L)	Royal Bank of Scotland Group PLC (RBS.L)	Skandinaviska Enskilda Banken AB (SEBa.ST)
Société Générale (SOGN.PA)	Standard Chartered PLC (STAN.L)	Swedbank AB (SWEDa.ST)
UBI Banca (UBI.MI)	UBS AG (UBSN.VX)	UniCredit (CRDI.MI)

**Distribution of Ratings:**



## IMPORTANT DISCLOSURES CONTINUED

Barclays Capital Inc. Equity Research has 1517 companies under coverage.

43% have been assigned a 1-Overweight rating which, for purposes of mandatory regulatory disclosures, is classified as a Buy rating; 51% of companies with this rating are investment banking clients of the Firm.

43% have been assigned a 2-Equal Weight rating which, for purposes of mandatory regulatory disclosures, is classified as a Hold rating; 44% of companies with this rating are investment banking clients of the Firm.

11% have been assigned a 3-Underweight rating which, for purposes of mandatory regulatory disclosures, is classified as a Sell rating; 34% of companies with this rating are investment banking clients of the Firm.

### **Barclays Capital offices involved in the production of equity research:**

London

Barclays Capital, the investment banking division of Barclays Bank PLC (Barclays Capital, London)

New York

Barclays Capital Inc. (BCI, New York)

Tokyo

Barclays Capital Japan Limited (BCJL, Tokyo)

São Paulo

Banco Barclays S.A. (BBSA, São Paulo)

Hong Kong

Barclays Bank PLC, Hong Kong branch (BB, Hong Kong)

Toronto

Barclays Capital Canada Inc. (BCC, Toronto)

Johannesburg

Absa Capital, a division of Absa Bank Limited (Absa Capital, Johannesburg)

This publication has been prepared by Barclays Capital; the investment banking division of Barclays Bank PLC, and/or one or more of its affiliates as provided below. This publication is provided to you for information purposes only. Prices shown in this publication are indicative and Barclays Capital is not offering to buy or sell or soliciting offers to buy or sell any financial instrument. Other than disclosures relating to Barclays Capital, the information contained in this publication has been obtained from sources that Barclays Capital believes to be reliable, but Barclays Capital does not represent or warrant that it is accurate or complete. The views in this publication are those of Barclays Capital and are subject to change, and Barclays Capital has no obligation to update its opinions or the information in this publication.

The analyst recommendations in this report reflect solely and exclusively those of the author(s), and such opinions were prepared independently of any other interests, including those of Barclays Capital and/or its affiliates.

Neither Barclays Capital, nor any affiliate, nor any of their respective officers, directors, partners, or employees accepts any liability whatsoever for any direct or consequential loss arising from any use of this publication or its contents. The securities discussed in this publication may not be suitable for all investors. Barclays Capital recommends that investors independently evaluate each issuer, security or instrument discussed in this publication and consult any independent advisors they believe necessary. The value of and income from any investment may fluctuate from day to day as a result of changes in relevant economic markets (including changes in market liquidity). The information in this publication is not intended to predict actual results, which may differ substantially from those reflected. Past performance is not necessarily indicative of future results.

This communication is being made available in the UK and Europe to persons who are investment professionals as that term is defined in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion Order) 2005. It is directed at, and therefore should only be relied upon by, persons who have professional experience in matters relating to investments. The investments to which it relates are available only to such persons and will be entered into only with such persons. Barclays Capital is authorized and regulated by the Financial Services Authority ('FSA') and member of the London Stock Exchange.

Barclays Capital Inc., US registered broker/dealer and member of FINRA ([www.finra.org](http://www.finra.org)), is distributing this material in the United States and, in connection therewith accepts responsibility for its contents. Any U.S. person wishing to effect a transaction in any security discussed herein should do so only by contacting a representative of Barclays Capital Inc. in the U.S. at 745 Seventh Avenue, New York, New York 10019. This material is distributed in Canada by Barclays Capital Canada Inc., a registered investment dealer and member of IIROC ([www.iiroc.ca](http://www.iiroc.ca)).

Subject to the conditions of this publication as set out above, Absa Capital, the Investment Banking Division of Absa Bank Limited, an authorised financial services provider (Registration No.: 1986/004794/06), is distributing this material in South Africa. Absa Bank Limited is regulated by the South African Reserve Bank. This publication is not, nor is it intended to be, advice as defined and/or contemplated in the (South African) Financial Advisory and Intermediary Services Act, 37 of 2002, or any other financial, investment, trading, tax, legal, accounting, retirement, actuarial or other professional advice or service whatsoever. Any South African person or entity wishing to effect a transaction in any security discussed herein should do so only by contacting a representative of Absa Capital in South Africa, 15 Alice Lane, Sandton, Johannesburg, Gauteng 2196. Absa Capital is an affiliate of Barclays Capital.

Non-U.S. persons should contact and execute transactions through a Barclays Bank PLC branch or affiliate in their home jurisdiction unless local regulations permit otherwise.

In Japan, foreign exchange research reports are prepared and distributed by Barclays Bank PLC Tokyo Branch. Other research reports are distributed to institutional investors in Japan by Barclays Capital Japan Limited. Barclays Capital Japan Limited is a joint-stock company incorporated in Japan with registered office of 6-10-1 Roppongi, Minato-ku, Tokyo 106-6131, Japan. It is a subsidiary of Barclays Bank PLC and a registered financial instruments firm regulated by the Financial Services Agency of Japan. Registered Number: Kanto Zaimukyokuchō (kinsho) No. 143.

Barclays Bank PLC, Hong Kong Branch is distributing this material in Hong Kong as an authorised institution regulated by the Hong Kong Monetary Authority. Registered Office: 41/F, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.

Barclays Bank PLC Frankfurt Branch is distributing this material in Germany under the supervision of Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). This material is distributed in Malaysia by Barclays Capital Markets Malaysia Sdn Bhd.

Barclays Bank PLC in the Dubai International Financial Centre (Registered No. 0060) is regulated by the Dubai Financial Services Authority. Barclays Bank PLC-DIFC Branch, may only undertake the financial services activities that fall within the scope of its existing DFSA licence.

Barclays Bank PLC in the UAE is regulated by the Central Bank of the UAE and is licensed to conduct business activities as a branch of a commercial bank incorporated outside the UAE in Dubai (Licence No.: 13/1844/2008, Registered Office: Building No. 6, Burj Dubai Business Hub, Sheikh Zayed Road, Dubai City) and Abu Dhabi (Licence No.: 13/952/2008, Registered Office: Al Jazira Towers, Hamdan Street, PO Box 2734, Abu Dhabi).

Barclays Bank PLC in the Qatar Financial Centre (Registered No. 00018) is authorised by the Qatar Financial Centre Regulatory Authority. Barclays Bank PLC-QFC Branch may only undertake the regulated activities that fall within the scope of its existing QFCRA licence. Principal place of business in Qatar: Qatar Financial Centre, Office 1002, 10th Floor, QFC Tower, Diplomatic Area, West Bay, PO Box 15891, Doha, Qatar.

This information has been distributed by Barclays Bank PLC. Related financial products or services are only available to Professional Clients as defined by the DFSA, and Business Customers as defined by the QFCRA.

IRS Circular 230 Prepared Materials Disclaimer: Barclays Capital and its affiliates do not provide tax advice and nothing contained herein should be construed to be tax advice. Please be advised that any discussion of U.S. tax matters contained herein (including any attachments) (i) is not intended or written to be used, and cannot be used, by you for the purpose of avoiding U.S. tax-related penalties; and (ii) was written to support the promotion or marketing of the transactions or other matters addressed herein. Accordingly, you should seek advice based on your particular circumstances from an independent tax advisor.

© Copyright Barclays Bank PLC (2010). All rights reserved. No part of this publication may be reproduced in any manner without the prior written permission of Barclays Capital or any of its affiliates. Barclays Bank PLC is registered in England No. 1026167. Registered office 1 Churchill Place, London, E14 5HP. Additional information regarding this publication will be furnished upon request.

